LivaNova PLC (NASDAQ:LIVN) Director Francesco Bianchi Sells 1,250 Shares

LivaNova PLC (NASDAQ:LIVN) Director Francesco Bianchi sold 1,250 shares of LivaNova stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total value of $63,737.50. Following the completion of the transaction, the director now directly owns 7,522 shares of the company’s stock, valued at approximately $383,546.78. This trade represents a 14.25 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

LivaNova Trading Down 1.2 %

Shares of LivaNova stock opened at $51.50 on Friday. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. The company has a market capitalization of $2.80 billion, a P/E ratio of 122.62 and a beta of 0.98. The stock has a fifty day simple moving average of $51.97 and a 200 day simple moving average of $51.55. LivaNova PLC has a 12-month low of $43.15 and a 12-month high of $64.47.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in LIVN. Fifth Third Bancorp increased its position in shares of LivaNova by 97.1% during the 2nd quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock valued at $37,000 after purchasing an additional 332 shares during the last quarter. Canada Pension Plan Investment Board purchased a new stake in shares of LivaNova during the 2nd quarter worth approximately $88,000. Central Pacific Bank Trust Division bought a new position in LivaNova during the third quarter valued at $178,000. TradeLink Capital LLC purchased a new stake in LivaNova in the second quarter worth $208,000. Finally, Captrust Financial Advisors bought a new stake in shares of LivaNova in the third quarter valued at $217,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on LIVN shares. Baird R W raised LivaNova from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 17th. The Goldman Sachs Group initiated coverage on shares of LivaNova in a research report on Friday, October 4th. They set a “buy” rating and a $65.00 target price on the stock. Mizuho dropped their price objective on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a report on Thursday, October 31st. StockNews.com lowered LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Saturday, November 16th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $75.00 target price on shares of LivaNova in a research report on Monday, November 25th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, LivaNova has a consensus rating of “Buy” and an average target price of $69.17.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.